Public COA audit
Retatrutide
Audited July 29, 2026
Several fields check out, but we found issues worth reviewing before you rely on this document.
- Legitimacy
- 88
- Confidence
- 87%
- Panels
- 2/7
- Purity (printed)
- 99.77%
Document details
Fields extracted from the certificate — not order or payment data.
- Batch / lot
- WL-RT30-P00521
- Identity method
- Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)
- Sample date
- 2026-07-08
- Issue date
- 2026-07-15
7-panel checklist
Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.
2 of 7 present · 2 passed · 0 failed · 0 reported · 5 missing
Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.
Identity
Tested · passed · core
Compound identity confirmed (e.g. HPLC, mass spec).
Retatrutide 32.66 mg
Purity
Tested · passed · core
Reported purity percentage for the analyte.
99.770%
Heavy metals
Not on this COA
Lead, arsenic, cadmium, mercury, or similar limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Microbial
Not on this COA
Bioburden / microbial limits testing.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Endotoxin
Not on this COA · core
LAL or chromogenic endotoxin assay.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Sterility
Not on this COA
Sterility testing where applicable.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Residual solvent / water
Not on this COA
Residual solvents or water content limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
How to read this
Had data · good
Panel present with a pass (or clear acceptance).
Had data · bad
Panel present with a fail — a concrete quality signal.
Had data · unclear
Value reported without an explicit pass/fail mark.
Missing
Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.
Findings
Evidence-linked observations from this audit.
High purity confirmed
99.77% purity by HPLC is excellent and typical for research-grade peptides
Blind test identity confirmation
Sample correctly identified as Retatrutide via blind test methodology against Semaglutide and Tirzepatide
Batch number present
Batch WL-RT30-P00521 from manufacturer Lumira clearly documented
Dates logical and current
Testing ordered 2026-07-01, sample received 2026-07-08, analysis conducted 2026-07-15 - all dates are sequential and within July 2026
Reputable testing laboratory
Janoshik Analytical is a well-known third-party testing lab for peptides and performance compounds
Verification system provided
Unique verification key X51LUUQ1DUM5 provided with URL www.janoshik.com/verify/ for independent verification
Limited testing scope
Only identity and purity panels performed; no heavy metals, microbial, endotoxin, sterility, or residual solvent testing
Professional presentation
Clean layout with QR code, signature, task number #203359, and sample photo included on page 2
PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.